Osiris Therapeutics (OSIR) Stock Price, News & Analysis

Company Overview

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Key Stats

• Today's Range: $18.99 to $18.99
• 50-Day Range: $18.99 to $18.99
• 52-Week Range: $7.01 to $19.30
• Volume: N/A
• Average Volume: 205,753 shs
• Market Capitalization: $655.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OSIR Stock Analysis - Frequently Asked Questions

How have OSIR shares performed this year?

Osiris Therapeutics' stock was trading at $18.99 on January 1st, 2024. Since then, OSIR shares have increased by 0.0% and is now trading at $18.99.
View the best growth stocks for 2024 here.

How do I buy shares of Osiris Therapeutics?

Shares of OSIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Osiris Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Osiris Therapeutics investors own include Sierra Wireless (SWIR), MiMedx Group (MDXG), Achillion Pharmaceuticals (ACHN), Mallinckrodt (MNK), Bristol-Myers Squibb (BMY), Ionis Pharmaceuticals (IONS) and Mesoblast (MESO).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:OSIR
• Previous Symbol: NASDAQ:OSIR
• CUSIP: 68827R10
• CIK: 1360886
• Web: www.osiristx.com
• Phone: 443-545-1800
• Fax: N/A
• Employees: 342
• Year Founded: 1992

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 34,528,000
• Free Float: N/A
• Market Cap: $655.69 million
• Optionable: Not Optionable
• Beta: N/A